Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization
We demonstrated in this analysis that the safety and efficacy of tisagenlecleucel in patients with r/r DLBCL in an Australian real-world setting were better than in the pivotal JULIET clinical trial and other registry studies. We also confirmed the importance of achieving early CR and normalizing the LDH levels at CAR-T cell infusion to reduce the risk of disease progression. Our results suggest that bridging therapy played an important role in optimizing outcomes by managing pre-CAR-T disease control.
Authors
- Phoebe Joy Ho
- Stephen Robert Larsen (ORCID: https://orcid.org/0000-0002-4867-291X)
- Liane Khoo
- Derek McCulloch
- James Favaloro
- Anthony Jeffrey (ORCID: https://orcid.org/0000-0003-4277-7478)
- Vinay Vanguru
- Christian Bryant (ORCID: https://orcid.org/0000-0001-9999-6968)
- Ann Solterbeck (ORCID: https://orcid.org/0000-0002-0432-0226)
- Edward Abadir (ORCID: https://orcid.org/0000-0002-4152-5079)
- Rebecca Wayte
- Christina Brown (ORCID: https://orcid.org/0000-0003-2811-8943)
- Scott Dunkley
- C. Burge
Institutions
- The University of Sydney (AU)
- Royal Prince Alfred Hospital (AU)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-08-19
- DOI
- https://doi.org/10.3389/fonc.2025.1633644
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Novartis Pharmaceuticals Corporation